Showing results (151-160 of 777) with videos related to

Sort By:
Pageof 78
British Journal of Haematology|October 13, 2015
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomideDeepika S Das, Arghya Ray, Yan Song, et al.
Cancer Research|December 17, 2005
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implicationsYu-Tzu Tai, Xian-Feng Li, Laurence Catley, et al.
British Journal of Haematology|September 29, 2011
Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cellsDharminder Chauhan, Madhavi Bandi, Ajita V Singh, et al.
Blood Cancer Journal|April 2, 2022
Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myelomaArghya Ray, Yan Song, Ting Du, et al.
Blood|December 8, 2009
Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myelomaDharminder Chauhan, Ajita V Singh, Bryan Ciccarelli, et al.
Cancer Cell|March 31, 2004
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumorsConstantine S Mitsiades, Nicholas S Mitsiades, Ciaran J McMullan, et al.
Oncogene|October 14, 2004
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cellsTeru Hideshima, Klaus Podar, Dharminder Chauhan, et al.
Cancer Research|August 17, 2005
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistanceHiroshi Yasui, Teru Hideshima, Noopur Raje, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 30, 2003
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implicationsConstantine S Mitsiades, Nicholas S Mitsiades, Ciaran J McMullan, et al.
Blood|April 2, 2005
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myelomaHiroshi Yasui, Teru Hideshima, Makoto Hamasaki, et al.
Pageof 78